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Abstract
The misuse of tranquilizer and sedative medications (i.e., use without a
prescription or at higher doses/longer periods of time than prescribed) is associated with
myriad negative sequalae, such as suicidal behaviors and increased risk of overdose. Yet,
prescription tranquilizer and sedative misuse has been largely overlooked by the
scientific community, clinicians, and policymakers. We addressed this gap in the
literature by characterizing subgroups of individuals with tranquilizer or sedative misuse,
based on their patterns of polysubstance use. The present study analyzed data from two
samples of individuals with past-month tranquilizer or sedative misuse: respondents of a
nationally-representative household survey (general population sample; N=970) and
individuals in substance use disorder treatment (clinical sample; N=451). Using latent
class analysis, we identified two patterns of polysubstance use in the general population
sample: (1) sedative misuse with low polysubstance use (approximately 16.6% of the
sample), and (2) tranquilizer misuse with high polysubstance use (83.4%). Correlates of
expected membership in the tranquilizer misuse with high polysubstance use class
included younger age, more motives for misuse, and use without a prescription. We also
identified two latent classes in the clinical sample: opioid use with high polysubstance
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use (approximately 73.1% of the sample) and binge alcohol use with moderate
polysubstance use (26.9%). Younger age and lower levels of anxiety sensitivity were
associated with expected membership in the opioid use with high polysubstance use
class. These results indicate that a majority of tranquilizer/sedative misuse does not occur
in isolation, but, rather, is part of a pattern of polysubstance use. This finding is
concerning, given the increased risk of overdose when tranquilizers and sedatives are
combined with other substances.
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Introduction
Prescription tranquilizers and sedatives represent several classes of central
nervous system depressants (e.g., benzodiazepines, barbiturates, z-drugs) that produce
anxiolytic, hypnotic, and anticonvulsant effects (National Institute on Drug Abuse, 2011).
Tranquilizers and sedatives, particularly benzodiazepines, are among the most commonly
prescribed psychiatric medications in the United States (U.S.) (Lindsley, 2012; Moore &
Mattison, 2017). In 2013, 13.5 million adults in the U.S. filled a benzodiazepine
prescription, representing a 65% increase since 1996 (Bachhuber, Hennessy,
Cunningham, & Starrels, 2016).
Although tranquilizers and sedatives are effective pharmacotherapies for anxiety
(Starcevic, 2014), insomnia (Atkin, Comai, & Gobbi, 2018; Holbrook, Crowther, Lotter,
& Endeshaw, 2001), and alcohol withdrawal (Amato, Minozzi, Vecchi, & Davoli, 2010),
they also produce positive subjective effects and subsequent self-administration, known
as abuse liability (de Wit & Griffiths, 1991; Griffiths & Johnson, 2005; J. D. Jones,
Mogali, & Comer, 2012). Accordingly, tranquilizer or sedative misuse refers to use of
these medications without a prescription, for longer periods of time or at higher doses
than prescribed, or for reasons other than prescribed (e.g., to get high) (National Institute
on Drug Abuse, 2018). Results from the National Survey on Drug Use and Health
(NSDUH) indicate that 2.2% of U.S. citizens ages 12 and older misused tranquilizers
(e.g., clonazepam, alprazolam, buspirone, cyclobenzaprine) in 2017, making tranquilizers
the third most commonly misused illicit or prescription substance in the U.S. (Center for
Behavioral Health Statistics and Quality, 2018). An additional 0.5% misused sedative
medications (e.g., barbiturates, temazepam, triazolam) (Center for Behavioral Health
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Statistics and Quality, 2018). As noted above, benzodiazepine prescriptions have
increased over the past two decades; however, rates of tranquilizer and sedative misuse
have remained relatively stable (Votaw, Geyer, Rieselbach, & McHugh, in press).
Estimating the prevalence of tranquilizer and sedative misuse in the U.S. is
complicated by methodological features of population-based surveys that provide
estimates of substance misuse and substance use disorders. Specifically, tranquilizers and
sedatives represent different drug classes in these surveys, even though both include
benzodiazepine products and have similar indications (e.g., insomnia, anxiety) (Center
for Behavioral Health Statistics and Quality, 2017; Johnston et al., 2018). Accordingly,
secondary data analyses of population-based data commonly combine these two classes
(Becker, Fiellin, & Desai, 2007; Goodwin & Hasin, 2002), while analyses of clinical data
have primarily examined benzodiazepine misuse, exclusively. Throughout this thesis, we
will refer to the misuse of tranquilizers and sedatives, in combination, though many
reviewed studies specifically examined benzodiazepine misuse.
Tranquilizer and Sedative Misuse: A Problem Unique to Polysubstance Users?
In the general population, polysubstance use (i.e., total number of substances
used) and other substance use disorders increase the risk of tranquilizer and sedative
misuse and dependence (Becker et al., 2007; Fenton, Keyes, Martins, & Hasin, 2010;
Goodwin & Hasin, 2002; Huang et al., 2006). Accordingly, rates of tranquilizer and
sedative misuse are much higher among those with other substance use disorders, as
compared to the general population. Among those with opioid use disorder,
approximately 50% of treatment-seekers (McHugh et al., 2017; Stein, Kanabar,
Anderson, Lembke, & Bailey, 2016; Vogel et al., 2013) and over 20% of those in the
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general population (Votaw, Witkiewitz, Valeri, Bogunovic, & McHugh, 2019) report
past-month tranquilizer or sedative misuse. Limited available evidence among those with
alcohol use disorder suggests that rates of past-month tranquilizer or sedative misuse are
approximately 2.7% in the general population (Votaw et al., 2019) and 19% among
treatment-seekers (McHugh, Geyer, Karakula, Griffin, & Weiss, 2018).
Even among those with substance use disorders, use of specific substances (e.g.,
marijuana, cocaine) and overall polysubstance use incrementally predict tranquilizer and
sedative misuse. For example, several studies among those in opioid use disorder
treatment indicate that cocaine use (Schuman-Olivier et al., 2013; Stein, Anderson,
Kenney, & Bailey, 2017), amphetamine use (Lavie, Fatséas, Denis, & Auriacombe, 2009;
Schuman-Olivier et al., 2013; Stein et al., 2017), marijuana use (Ghitza, Epstein, &
Preston, 2008), and more total substances used (Lavie et al., 2009; Schuman-Olivier et
al., 2013) are associated with increased risk of misuse. Polysubstance use has also been
associated with misuse among those seeking treatment for alcohol use disorder (McHugh
et al., 2018). In a recent analysis of NSDUH data, each additional substance used in the
past year was associated with 1.4 greater odds of past-month tranquilizer or sedative
misuse among those with opioid use disorder, 2.3 greater odds among those with alcohol
use disorder, and 1.5 greater odds among those with co-occurring opioid and alcohol use
disorders (Votaw et al., 2019).
The high prevalence of tranquilizer and sedative misuse among those with
substance use disorders might be partly explained by a greater number of motives, or
reasons, for misuse in these populations. Tranquilizers and sedatives are most commonly
misused to reduce negative affective (e.g., anxiety) and somatic (e.g., insomnia) states
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(Votaw et al., in press). However, individuals with opioid use disorder report additional
motives for tranquilizer and sedative misuse, including use to get high, to cope with
withdrawal, and to modify the effects of other substances (e.g., increasing effects of
opioids, decreasing effects of stimulants) (Gelkopf, Bleich, Hayward, Bodner, &
Adelson, 1999; Mateu-Gelabert et al., 2017; Vogel et al., 2013). Thus, several features of
chronic substance use (e.g., high levels of negative affective and somatic symptoms,
decreased reward sensitivity; Koob & Le Moal, 2008), might motivate those with
substance use disorders to misuse tranquilizers and sedatives for myriad reasons, thus
increasing the overall prevalence of misuse.
Predictors of Tranquilizer and Sedative Misuse
These reviewed findings raise the following questions: does tranquilizer and
sedative misuse occur independent of polysubstance use? If so, what motivates the
misuse of tranquilizers and sedatives among individuals without polysubstance use?
Several population-based studies have identified factors that are uniquely associated with
risk of tranquilizer and sedative misuse, even when controlling for other substance use
and substance use disorders. Sociodemographic factors consistently associated with
misuse include younger age (i.e., ages 18-25) and non-Hispanic white racial/ethnic
identity (Votaw et al., in press). Although several large, population-based studies indicate
that female gender is associated with tranquilizer and sedative misuse, males typically
have higher risk of misuse when controlling for receipt of a tranquilizer/sedative
prescription (Votaw et al., in press). Females and non-Hispanic white individuals are
more likely to receive a benzodiazepine prescription (Olfson, King, & Schoenbaum,
2015), which might increase risk of misuse due to greater availability and/or psychiatric
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severity. Indeed, receipt of a tranquilizer or sedative prescription is associated with 1.9
greater odds of misuse and 2.6 greater odds of a use disorder, even when controlling for
lifetime anxiety disorder diagnoses (Fenton et al., 2010).
Numerous general population studies have identified associations between
psychiatric distress (e.g., psychiatric disorders, general distress) and tranquilizer/sedative
misuse and use disorder (Votaw et al., in press). Among those with opioid use disorder,
symptoms of anxiety and depression and affective vulnerabilities have been consistently
associated with tranquilizer or sedative misuse (Eiroa-Orosa et al., 2010; McHugh et al.,
2017; Stein et al., 2017). Anxiety sensitivity—a trait-like vulnerability characterized by
the fear of anxiety symptoms and sensations—has been associated with regular
tranquilizer or sedative misuse (Hearon et al., 2011), greater frequency of misuse
(McHugh et al., 2017), and dependence (Conrod, Pihl, Stewart, & Dongier, 2000). These
findings have been recently replicated among those with alcohol use disorder (McHugh et
al., 2018).
There is also evidence for associations between physical health issues and
tranquilizer/sedative misuse among the general population, those with opioid use
disorder, and other subgroups, such as healthcare workers and adolescents presenting to
the emergency department (Votaw et al., in press). However, measures of physical health
examined have varied widely, including self-reported general health, pain severity, sleep
dysfunction, and disability status.
Functional Consequences Associated with Tranquilizer and Sedative Misuse
Given high rates of tranquilizer and sedative misuse among those with opioid use
disorder (see above), studies examining functional consequences associated with misuse

5

TRANQUILIZER/SEDATIVE MISUSE AND PATTERNS OF POLYSUBSTANCE
USE
have primarily enrolled individuals with opioid use disorder and/or those with injection
drug use. Accordingly, most functional consequences associated with tranquilizer and
sedative misuse are particularly relevant to individuals with substance use disorders, such
as overdose, HIV/HCV infection, treatment attrition, and opioid relapse. Unless
otherwise specified, the literature reviewed below will focus on functional consequences
associated with tranquilizer and sedative misuse among those with opioid use disorder
and/or injection drug use.
The most consistent—and most concerning—consequence associated with misuse
is the increased risk of heart rate and respiratory depression when tranquilizers and
sedatives, particularly benzodiazepines, are combined with opioids and/or alcohol
(Gudin, Mogali, Jones, & Comer, 2013). Overdose deaths involving benzodiazepines
(often in combination with other substances) have increased more than 300% from 20022015 (National Institute on Drug Abuse, 2017). Among individuals with opioid misuse
and opioid use disorder, tranquilizer and sedative misuse and dependence have been
retrospectively (Galea et al., 2006; Hakansson, Schlyter, & Berglund, 2008; Kerr et al.,
2007; Maloney, Degenhardt, Darke, & Nelson, 2009; Wines Jr., Saitz, Horton, LloydTravaglini, & Samet, 2007) and prospectively (Gossop, Stewart, Treacy, & Marsden,
2002) associated with opioid overdose. Beyond increasing risk of overdose, those with
tranquilizer or sedative misuse have elevated rates of HIV (Ickowicz et al., 2015) and
Hepatitis C (Bleich et al., 1999) infection, as well as other sexually transmitted infections
(S Darke, Hall, Ross, & Wodak, 1992). Misuse is also associated with a history of
attempted suicide among several populations, including those in the general population
(Borges, Walters, & Kessler, 2000), adolescents (Kokkevi et al., 2012), those with
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alcohol dependence, (Preuss et al., 2003) and those with opioid use disorder and/or
injection drug use (Artenie, Bruneau, Roy, et al., 2015; Artenie, Bruneau, Zang, et al.,
2015; Shane Darke, Ross, Lynskey, & Teesson, 2004; Wines, Saitz, Horton, LloydTravaglini, & Samet, 2004). Accordingly, tranquilizer and sedative misuse and
dependence are associated with overall mortality among those with opioid use disorder
(Pavarin, 2015; Peles, Schreiber, & Adelson, 2010).
In addition, misuse of tranquilizer and sedative medications is associated with a
number of behavioral consequences among those with opioid misuse. Those with misuse
are more likely to report more frequent injection drug use, unsafe injection behaviors
(e.g., sharing injection equipment), and risky sexual practices (e.g., unsafe sex,
prostitution) (Darke et al., 1992; Darke, Swift, Hall, & Ross, 1993; Tucker et al., 2016),
which might explain the associations between tranquilizer/sedative misuse and infectious
disease. Misuse is also associated with increased risk of criminal involvement,
particularly property crime and selling drugs (Comiskey, Stapleton, & Kelly, 2012; Shane
Darke et al., 2010; Horyniak et al., 2016). Several studies indicate that misuse is
associated with opioid use disorder treatment attrition (Eiroa-Orosa et al., 2010; Peles et
al., 2010; Schiff, Levit, & Moreno, 2007; White et al., 2014) and continued substance use
throughout treatment (Brandt, Taverna, & Hallock, 2014; Shane Darke et al., 2010; Naji
et al., 2016), though other studies have not identified an effect of misuse on opioid use
disorder treatment outcomes (Proctor et al., 2015; Schuman-Olivier et al., 2013).
Despite relatively consistent associations between tranquilizer and sedative
misuse and poor outcomes, explanations for these associations are unclear. Some authors
have posited that tranquilizer and sedative misuse might increase risk of functional
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consequences by acute decreases in inhibition (Artenie, Bruneau, Roy, et al., 2015;
Artenie, Bruneau, Zang, et al., 2015; S Darke et al., 1992; Wines et al., 2004), while
others have suggested that those with tranquilizer or sedative misuse might have greater
psychiatric severity (both as an antecedent and consequences of tranquilizer or sedative
misuse), which is associated with poorer outcomes (Artenie, Bruneau, Roy, et al., 2015;
Artenie, Bruneau, Zang, et al., 2015; Naji et al., 2016; Wines et al., 2004). It is also
plausible that greater substance use involvement among those with tranquilizer or
sedative misuse could explain the associations between misuse and poor functional
outcomes, but this hypothesis has not been systematically investigated. Notably, only one
of the previously reviewed studies controlled for level of polysubstance use (Darke et al.,
2010), despite evidence that polysubstance use was also associated with negative
outcomes in several of the studies (Darke et al., 2004; Gossop et al., 2002; Wines et al.,
2004; Wines Jr. et al., 2007). Another previous study found that tranquilizer/sedative
misuse was associated with recent injection drug use in bivariate analyses, but this effect
was mitigated when controlling for polysubstance use (as well as other factors that were
significant in bivariate analyses, including female gender, having a sexual partner who
injected drugs, and poorer general health) (Darke, Swift, Hall, & Ross, 1994). Thus, the
associations between tranquilizer and sedative misuse and functional consequences might
be explained by greater levels of substance use involvement.
Current Studies
Most studies characterizing tranquilizer and sedative misuse have enrolled
samples with severe substance use presentations, particularly those with opioid use
disorder (Bouvier et al., 2017; Ghitza et al., 2008; Lavie et al., 2009; McHugh et al.,
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2017; Schuman-Olivier et al., 2013; Stein et al., 2017, 2016; Vogel et al., 2013).
Although there is robust evidence to suggest that those with polysubstance use are the
most vulnerable to tranquilizer and sedative misuse (Becker et al., 2007; Fenton et al.,
2010; Goodwin & Hasin, 2002; Huang et al., 2006; Votaw et al., 2019), it is unclear
whether misuse occurs in isolation. The present study aimed to address this gap by using
latent class analysis (LCA) to identify patterns of polysubstance use among those with
past-month tranquilizer or sedative misuse. LCA is a form of mixture modeling that uses
a person-centered approach to detect heterogeneity in a population (Nylund, 2007).
Utilizing latent class analysis provides an opportunity to examine distinct patterns of
polysubstance use among a larger population of those with current tranquilizer or
sedative misuse, including determining the presence (or lack thereof) of individuals with
low levels of polysubstance use.
The second aim of the study was to examine sociodemographic, clinical (e.g.,
measures of psychiatric distress), and substance use (e.g., motives for
tranquilizer/sedative misuse) correlates of identified latent classes. This aim was
accomplished through the use of multinomial logistic regression models, using a modelbased approach. Examining correlates of identified classes allowed for the identification
of potential risk factors for more severe polysubstance use. Characterizing those with
lower levels of polysubstance use helped to determine populations who have been
overlooked in studies examining the etiology of tranquilizer and sedative misuse, who
may be important targets for future research.
Lastly, we examined functional consequences associated with identified latent
classes using distal outcome analysis. Distal outcome analysis estimates the proportion of
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individuals in a latent class who will experience a particular outcome. A number of
consequences have been consistently associated with tranquilizer and sedative misuse,
including risk of overdose (Galea et al., 2006; Hakansson et al., 2008; Kerr et al., 2007;
Maloney et al., 2009; Wines Jr. et al., 2007), infectious disease (Bleich et al., 1999; S
Darke et al., 1992; Ickowicz et al., 2015), risky sexual behavior/risky injection practices
(S Darke et al., 1992, 1993; Tucker et al., 2016), increased criminal involvement
(Comiskey et al., 2012; Shane Darke et al., 2010; Horyniak et al., 2016), suicidal
ideation/attempt (Artenie, Bruneau, Roy, et al., 2015; Artenie, Bruneau, Zang, et al.,
2015; Shane Darke et al., 2004; Wines et al., 2004), and poor substance use disorder
treatment outcomes (Brandt et al., 2014; Shane Darke et al., 2010; Naji et al., 2016).
Authors of these studies have posited that these associations are due to the inhibitory
effects of tranquilizers and sedatives, increased psychiatric distress and functional
severity among those with tranquilizer or sedative misuse, or both (Artenie, Bruneau,
Roy, et al., 2015; Artenie, Bruneau, Zang, et al., 2015; Naji et al., 2016; Wines et al.,
2004). No studies to date have suggested or examined the possibility that these
associations are due to increases in overall polysubstance use among those with misuse.
Examining functional consequences as a function of polysubstance use involvement
evaluated initial evidence for this hypothesis.
Importantly, we executed these aims in two studies enrolling distinct samples: (1)
respondents of a population-based household survey (i.e., general population sample) and
(2) individuals in inpatient detoxification treatment for substance use disorders (i.e.,
clinical sample). The general population sample allowed for the potential to detect a
subgroup(s) with lower levels of polysubstance use. However, if we utilized this sample
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alone, those with more severe substance use presentations might have been identified as
one (or multiple) homogenous group(s). Thus, we also utilized a clinical sample to detect
further heterogeneity among those with severe substance use presentations.
Characterizing patterns of polysubstance use among a clinical sample with substance use
disorders is important, given that this population displays high rates of tranquilizer and
sedative misuse and the consequences associated with misuse.
Hypotheses
First, we hypothesized that we would identify distinct patterns of polysubstance
use among those with tranquilizer or sedative misuse. Among the general population
sample, we hypothesized that identified latent classes would be interpreted as: (1) low
levels of polysubstance use, (2) alcohol/marijuana use, and (3) high levels of
polysubstance use. These hypotheses were informed by a previous study that utilized
LCA to identify patterns of polysubstance use among a general population sample of
individuals with prescription amphetamine misuse (Chen et al., 2014). The most common
latent class in this analysis was the low polysubstance use class, consisting of
approximately 53.3% of the sample. However, we hypothesized that the high
polysubstance use class would be the most prevalent in our sample, given robust
associations between polysubstance use and tranquilizer/sedative misuse. Among the
clinical sample, given that nearly all participants have either alcohol or opioid use
disorder, we hypothesized that identified latent classes will be interpreted as: (1)
concurrent alcohol use, (2) concurrent opioid use, and (3) high levels of polysubstance
use.
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Second, we hypothesized that the identified latent classes would display distinct
sociodemographic and substance use characteristics. For example, we hypothesized that
female gender, older age, and minority racial/ethnic status would be associated with the
class(es) characterized by lower levels of polysubstance use, while male gender, younger
age, white race, and greater psychiatric and physical distress would be associated with
higher levels of polysubstance use. We also expected that a greater number of reasons, or
motives, for tranquilizer/sedative misuse would be associated with greater levels of
polysubstance use, as would use without a prescription. Finally, we hypothesized that
individuals with expected classification in the polysubstance use class(es) would display
the highest proportions of functional consequences, such as criminality, suicidal
behaviors, and sexually transmitted infections.
Study 1: General Population Sample
Method
Data source and participants. This study entailed a secondary data analysis of
National Survey on Drug Use and Health (NSDUH) respondents. The NSDUH is an
annual, population-based survey of U.S. citizens ages 12 and older. The purpose of the
NSDUH is to identify nationwide prevalence rates for substance use misuse and
substance use disorders. Households with potential respondents are identified through an
independent, multistage probability sample within the 50 states and Washington D.C. In
order to protect participant confidentiality, a de-identified subset of the total annual
sample is available for public use. Detailed NSDUH methodology has been previously
reported (Center for Behavioral Health Statistics and Quality, 2017).
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The present study utilized combined data from the 2015 and 2016 public use data
files. Participants for the present analysis were adult respondents who reported the misuse
of tranquilizer or sedative medications in the previous month (N=988).
Measures.
Sociodemographics. The following sociodemographic measures were included in
the present analysis: gender, age (categorized as 18-25 years old, 26-34, 35 and older),
and racial/ethnic identity (non-Hispanic White vs. racial/ethnic minority).
Substance use. To determine lifetime prescription tranquilizer (e.g., alprazolam,
lorazepam, diazepam, buspirone) or sedative (e.g., barbiturates, temapzepam, triazolam,
zolpidem) use, participants were shown cards with pictures and names of these
medications and specified which, if any, they had ever used. Participants with lifetime
tranquilizer or sedative use indicated if they had ever misused these medications, which
was defined as use at higher doses/more frequently than prescribed, for reasons other than
prescribed, or use without a prescription. Those with lifetime tranquilizer or sedative
misuse then indicated the length of time since their last episode of misuse. The frequency
of past-year and past-month tranquilizer and sedative misuse was also assessed. Those
with past-month tranquilizer or sedative misuse were included in the present analysis. We
decided to include those with past-month tranquilizer or sedative misuse, given that both
classes include benzodiazepine products and are prescribed for similar indications (e.g.,
sleep, anxiety). Combining these classes is consistent with previous analyses of NSDUH
data (Becker et al., 2007; Goodwin & Hasin, 2002).
Similar procedures as described above were used to determine past-month
prescription opioid and amphetamine misuse. Participants were also asked if they had
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ever used any illicit substances (e.g., marijuana, cocaine/crack cocaine,
methamphetamine, heroin, hallucinogens, inhalants) or alcohol. Binge alcohol use (4/5+
drinks for men/women, respectively) was also assessed. Participants with lifetime use of
illicit drugs or alcohol answered a standardized set of questions to determine length of
time since their most recent use and frequency of use. The present analysis utilized data
on past-month use (yes/no) of a range of substances (e.g., prescription amphetamines,
prescription opioids, marijuana, cocaine, heroin, binge alcohol use). Measures of pastmonth frequency of use were also utilized and were recoded into categorical measures of
frequency (0, 1–3, 4–8, 9–15, or 16–30 days), which were informed by the Brief
Addiction Monitor (Cacciola et al., 2013).
Misuse behaviors and motives. Those with past-year tranquilizer or sedative
misuse reported their behaviors that comprised misuse for both tranquilizers and
sedatives, separately. Specifically, participants were asked: “Which of these statements
describe your use of tranquilizers/sedatives at any time in the past 12 months?” Response
options included the following: used without my own prescription in the past 12 months,
used in greater amounts than prescribed in the past 12 months, used more often than
prescribed in the past 12 months, used over longer periods of time than prescribed in the
past 12 months, and used in some other way that was not directed by a physician in the
past 12 months. Participants were able to choose more than one response. Any misuse of
tranquilizer or sedative medications without a prescription in the past year (termed
nonmedical use) vs. misusing one’s own prescription for longer periods of time, at higher
doses, or for longer periods of time than prescribed (termed medical misuse), was
included as a dichotomous variable in the present analysis.
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To determine motives, or reasons, for tranquilizer and sedative misuse,
participants were asked: “Now think about the last time you used tranquilizers/sedatives
in any way a doctor did not direct you to. What were the reasons you used
tranquilizers/sedatives the last time?” Notably, this question only referred to the
participants’ last episode of misuse. Response options included the following: to
relax/relieve tension, to experiment/to see what tranquilizers/sedatives are like, to feel
good/get high, to help with sleep, to help me with feelings/emotions, to increase/decrease
the effect(s) of some other drug, because I’m hooked/have to have sedatives, and some
other reason. Participants were able to choose more than one response and they reported
motives for tranquilizer and sedative misuse separately. Participants’ total number of
motives at their last episode of misuse was included in the present analysis. For those
with both tranquilizer and sedative misuse, motives were totaled for their last misuse of
tranquilizers, as opposed to sedatives, given that a majority of the sample reported
tranquilizer misuse in the previous month.
Mental health. The measure of psychiatric distress utilized was the Kessler
Psychological Distress Scale (K6 Scale) (Kessler et al., 2003). Notably, this scale is only
administered to participants over the age of 18, which limited our analysis to adult
respondents. The Kessler K6 scale is a nonspecific measure of psychiatric distress that
includes 6 questions about the frequency of mood and anxiety symptoms. Specifically,
participants were asked to answer the following questions pertaining to the previous
month: “How often did you feel nervous?”, “How often did you feel hopeless?”, “How
often did you feel restless or fidgety?”, “How often did you feel so sad or depressed that
nothing could cheer you up?”, “how often did you feel that everything was an effort?”,
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and “how often did you feel down on yourself, no good, or worthless?” Response options
ranged from “none of the time” to “all of the time,” representing a potential range of
scores from 0 to 24. Higher scores indicate greater psychiatric distress in the previous
month. The K6 scale has demonstrated satisfactory internal consistency reliability
(Cronbach’s =0.89) and construct validity, as evidenced by the ability to differentiate
those with and without serious mental illness (Kessler et al., 2003).
Functional consequences. Functional consequences were selected based on prior
evidence of association with tranquilizer and sedative misuse (Votaw et al., in press) and
included: past-year deviant behavior, past-year arrest, past-year suicidal ideation, pastyear injection drug use, and past-year sexually transmitted infection (STI).
Consistent with previous analyses using NSDUH data (Chen et al., 2014; Hedden
et al., 2010), past-year deviant behavior was determined by responses to the following
questions: “During the past 12 months, how many times have you attacked someone with
the intent to seriously hurt them?”, “During the past 12 months, how many times have
you sold illegal drugs”, and “During the past 12 months, how many times have you stolen
or tried to steal anything worth more than US $50?” Participants who reported any of
these behaviors greater than one time were classified has having a past-year deviant
behavior.
Past-year arrest status was determined by a question that asked participants “Not
counting minor traffic violations, how many times during the past 12 months have you
been arrested and booked for breaking a law?” Participants who were arrested at least
once in the previous year were categorized as having a past-year arrest.

16

TRANQUILIZER/SEDATIVE MISUSE AND PATTERNS OF POLYSUBSTANCE
USE
Past-year suicidal ideation was determined by an affirmative response to the
following question: “At any time in the past 12 months, did you seriously think about
trying to kill yourself?”
To determine past-year injection drug use, participants answered a question that
asked if they had ever used a needle to inject any drug. Those with lifetime injection drug
use indicated the amount of time since their last injection drug use.
Finally, STI status was determined by participants’ responses to the following
questions: “During the past 12 months, did you have a sexually transmitted disease such
as chlamydia, gonorrhea, herpes or syphilis?” Participants were told to base their
response on conversations they’ve had with their doctor.
Statistical analyses. First, latent class analysis (LCA) was utilized to identify
patterns of polysubstance use in the previous month. LCA is a person-centered approach
used to identify distinct subpopulations of individuals, based on similar responses to
indicator variables. LCA estimates two parameters: (1) probabilities of endorsing the
indicators, given latent class membership (i.e., item response probabilities), and (2) the
prevalence of each class in the population (i.e., class probability) (Nylund, 2007).
Indicators for the current analysis were past-month misuse of prescription
medications (e.g., prescription amphetamines, prescription opioids), illicit drugs (e.g.,
marijuana, cocaine, heroin, etc.), and binge alcohol use. Substances that were endorsed
by <5% of the sample were combined with other substances of the same class (e.g.,
combining prescription amphetamine and methamphetamine use) or were excluded from
analyses. The LCA was first estimated with a 1-class solution and increasing number of
classes were estimated until the optimal model was identified. Model fit was assessed
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using the Bayesian Information Criteria (BIC), where a lower BIC indicates a better
fitting model, and the sample size adjusted Bayesian Information Criteria (aBIC), which
adds a penalty for increasing parameters related to sample size. The optimal number of
classes was identified by the lowest BIC (or the greatest rate of decrease in BIC) and
aBIC and theoretical interpretability. Notably, we did not report the Lo-Mendell-Rubin
adjusted likelihood ratio test (LRT) as an indicator of model fit given that LRT estimates
do not account for complex sampling designs, such as those used by the NSDUH (see
below for details on variables accounting for complex sampling designs; Muthén, 2016).
Model entropy, a measurement of classification precision, was also interpreted and
reported, with entropy greater than .80 indicating good classification precision.
All models were estimated with three different combinations of indictors and
were evaluated for theoretical interpretability. First, indicators for the latent class analysis
were included as binary (yes/no) past-month use of alcohol and illicit/prescription
substances (LCA iteration 1). Second, for substances that were used by a high proportion
of the sample in the previous month (i.e., >20%), categorical frequency indicators were
utilized (LCA iteration 2). Lastly, a frequency indicator for past-month tranquilizer
misuse and a binary indicator for past-month sedative misuse were added to the model
(LCA iteration 3).
Potential predictors of latent class membership were included as covariates in the
LCA with latent class membership as a categorical outcome variable. Predictors were
factors that have previously demonstrated associations with the incidence and severity of
tranquilizer and sedative misuse (Votaw et al., in press), and included: age (18-25, 26-34,
35+), gender, race/ethnicity (non-Hispanic white vs. racial/ethnic minority), total number
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of motives for participants’ last misuse of tranquilizers or sedatives, misuse behaviors
(nonmedical use vs. medical misuse), and total K6 score in the previous month. Effect
sizes reported are adjusted odds ratios (aOR), controlling for all covariates in the model.
Finally, distal outcome analysis was utilized to determine functional
consequences associated with latent class membership, using the BCH approach
(Asparouhov & Muthén, 2014). The BCH approach weights observations inversely to
their classification error, or uncertainty. Thus, results were interpreted as the proportions
of individuals within each identified latent class who were expected to experience the
distal outcome, after weighting for classification error. Weighted Chi-square analyses
were utilized to identify statistically significant differences in the proportion of distal
outcomes across identified latent classes. The distal outcomes in the present analysis
were functional consequences that have previously been associated with tranquilizer and
sedative misuse (Votaw et al., in press), including the following: past-year deviant
behavior, past-year arrest, past-year suicidal behavior, past-year injection drug use, and
past-year STI.
SPSS version 25 was used to prepare data and compute descriptive statistics; all
other analyses were conducted in MPlus version 8 (L. Muthén & Muthén, 2017).
Descriptive statistics represent unweighted prevalence rates; all other analyses accounted
for the complex sampling procedures of the NSDUH (e.g., oversampling youth and
minorities) using the nesting (to capture stratification and to identify clustering) and
weighting variables provided in the public use dataset. Maximum likelihood estimation
was used to account for missing data in the indicator variables. Listwise deletion was
utilized for missing data on predictor variables, and therefore individuals with missing
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data on any of the covariate variables were excluded from all analyses. Individuals with
missing data on distal outcomes were excluded from BCH analyses, but not from the
LCA models.
Results
Participants and descriptive statistics. A total of 988 participants reported pastmonth tranquilizer or sedative misuse. Data from 18 participants were missing on
predictor variables (1.8% of the total sample), and therefore 970 individuals were
included in the LCA. All 18 participants with missing data did not answer the question
regarding misuse behaviors (i.e., nonmedical use vs. medical misuse) and 10 of these
participants were also missing data on motives for misuse. Participants with missing data
on predictor variables were significantly more likely to endorse past-month hallucinogen
use (27.8% vs. 12.3%; X2(1)=3.87, p =.049), but did not differ from those with complete
data on any other indicator variables. Those with missing data on predictor variables were
also significantly more likely to identify as a racial/ethnic minority group (50% vs.
28.7%; X2(1)=3.91, p =.048). An additional 39 participants were missing data on
functional consequences (4.0% of the 970 participants included in the LCA) and were
therefore excluded from distal outcome analyses. Participants with missing data on
functional consequences were significantly more likely to report past-month marijuana
use (71.8% vs. 55.7%; X2(1)= 3.92, p =.048), past-month hallucinogen use (25.6% vs.
11.7%; X2(1)=6.75, p=.009), be 18 to 25 years of age (74.4% vs. 46.5%; X2(1)=11.64,
p=.001), and identify as a racial/ethnic minority group (53.8% vs. 27.6%; X2(1)=12.61, p
<.001).
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Sociodemographic, clinical, and substance use data for the 970 participants
included in the LCA are reported in Table 1. Approximately half of the sample was
female (52.9%), a majority (71.3%) identified as non-Hispanic white, and nearly half of
the sample (47.6%) was between the ages of 18-25. A majority of the sample was
employed full-time (47.5%) or reported an “other” employment status (e.g., keeping
house, student; 24.3%) and completed a high school education (26.1%) or completed
some college or an associate’s degree (39.4%). The mean K6 score for the sample was
9.3 (SD=6.1; range=0-24; skewness=.41; kurtosis=-.52), indicating moderate levels of
psychiatric distress (Prochaska, Sung, Max, Shi, & Ong, 2012).
Participants primarily reported past-month tranquilizer misuse only (82.5%),
followed by sedative misuse only (11.5%) and the misuse of both tranquilizer and
sedative medications in the previous month (6.0%). Approximately 74.9% of participants
reported the use of tranquilizer/sedative medications without a prescription in the past 12
months. Participants reported a mean of 1.7 motives at their last episode of tranquilizer or
sedative misuse (SD=1.1 SD=6.1; range=1-7; skewness=1.66; kurtosis=2.61).
The incidence and frequency of use for each substance category is presented in
Table 2. Other than tranquilizers, binge alcohol use was the most frequently reported
substance category, followed by marijuana and prescription opioid misuse. Notably,
inhalant use was not included in the present analyses due to the low rate of use in the
sample (n=26; 2.7% of the sample). Lastly, deviant behavior was the most commonly
endorsed functional consequence in the present sample (27.6% of those with complete
data), followed by suicidal ideation (21.6%), arrest (14.0%), intravenous drug use (8%),
and diagnosis of a STI (7.8%).
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Latent class analyses. BIC, aBIC, and entropy for the 1- through 4-class
solutions for all three iterations of indicators are presented in Table 3. As previously
described, models were first estimated for the LCA with binary (yes/no) indicators for
past-month binge alcohol, marijuana, prescription opioid, cocaine, hallucinogen, heroin,
and amphetamine use. In LCA iteration 2, binary indicators were retained for past-month
marijuana, cocaine, hallucinogen, heroin, and amphetamine use, but indicators for the
past-month frequency of use (0, 1–3, 4–8, 9–15, or 16–30 days) were utilized for binge
alcohol use and prescription opioid misuse. Although marijuana use was also commonly
reported, we chose to retain a binary indicator for marijuana use given that the majority
of participants either did not use marijuana (43.7%) or misused marijuana at the highest
possible frequency (16+ days of use; 31.8%). Finally, in LCA iteration 3, binary
indicators were utilized for all substance categories included in the previous iterations
(i.e., past-month binge alcohol, marijuana, prescription opioid, cocaine, hallucinogen,
heroin, and amphetamine use), but two indicators were added to the models: a frequency
indicator for past-month tranquilizer misuse and a binary indicator for past-month
sedative misuse. A binary indicator was utilized for sedative misuse, as opposed to a
frequency indicator, given the low rate of any sedative misuse in our sample (17.5%).
For all three LCA iterations, BIC and aBIC decreased from the 1- to 2-class
models, from the 2- to 3-class models, and from the 3- to 4-class models. However, in all
three iterations, the rate of decrease was greatest from the 1- to 2-class models. To
prevent over-extraction of latent classes and to increase parsimony, we selected the 2class solution of LCA iteration 3 as the final model. This solution was also chosen
because of theoretical interpretability and classification precision (entropy=0.981). The
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first latent class (tranquilizer misuse with high polysubstance use) comprised
approximately 83.4% of the sample. This latent class was characterized by a 100%
probability of reporting past-month tranquilizer misuse, high probabilities of binge
alcohol use and marijuana use, and moderate probabilities of cocaine, prescription opioid,
and amphetamine use. The second latent class (sedative misuse with low polysubstance
use) consisted of approximately 16.6% of the sample and displayed a 100% probability of
reporting past-month sedative misuse, moderate probabilities of binge alcohol, marijuana,
and prescription opioid misuse, and low probabilities of all other substance use. The
probabilities of endorsing each substance category, by latent class, are presented in
Figure 1.
Given that the addition of past-month tranquilizer and sedative misuse improved
classification precision, we examined the incidence of past-month substance use by
tranquilizer misuse only, sedative misuse only, and both tranquilizer and sedative misuse
(see Table 4). Consistent with findings from the LCA, those with past-month tranquilizer
misuse (either alone or in combination with sedative misuse) had significantly higher
rates of past-month use for all substances, with the exception of heroin and hallucinogens
(likely due to inadequate power).
Logistic regression. Results of the logistic regression predicting expected
membership in the LCA classes are presented in Table 5. The two older age groups were
associated with lower odds of membership in the tranquilizer misuse with high
polysubstance use class, as compared to the sedative misuse with low polysubstance use
class (aOR=0.40, 95% CI=0.21, 0.76, p=0.005; aOR=0.27, 95% CI=0.14, 0.50, p<0.001;
for 26-34 vs. 18-25 and 35+ vs. 18-25, respectively). In addition, a greater number of
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motives for participants’ last episode of misuse (aOR=1.87, 95% CI=1.19, 2.93, p=0.006)
and nonmedical use in the past year (aOR=2.27, 95% CI=1.31, 3.91, p=0.003) were
associated with greater odds of membership in the tranquilizer misuse with high
polysubstance use class. Gender, racial/ethnic identity, and psychiatric distress were not
significantly associated with class membership (ps>0.05)
Distal outcome analysis. Differences in functional outcomes by latent class are
presented in Figure 2. Those in the tranquilizer misuse with high polysubstance use class
had significantly higher rates of past-year arrest, as compared to the sedative misuse with
low polysubstance use class (12.3% vs. 5.6%; X2(1)=4.17, p =.041). However, there were
no statistically significant differences between the two latent classes on any other
functional outcome (p>0.05).
Discussion
The misuse of tranquilizer and sedative medications is an emerging public health
problem that has been largely overlooked by clinicians, the scientific community, and
policymakers (Lembke, Papac, & Humphreys, 2018). The present study aimed to address
this gap in the literature by examining patterns of polysubstance use among a general
population sample of adults with tranquilizer and sedative misuse. The present analysis
identified two distinct latent classes of polysubstance use: tranquilizer misuse with high
polysubstance use and sedative misuse with low polysubstance use. An expected majority
of the sample (83.4%) demonstrated a pattern characterized by high probabilities of
misusing tranquilizers and numerous other substances, such as binge drinking, marijuana,
prescription opioids, cocaine, and amphetamines. These results indicate that a majority of
tranquilizer misuse does not occur in isolation, but, rather, is part of a pattern of
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polysubstance use. These findings corroborate consistent and robust associations between
the use of other substances and risk of tranquilizer and sedative misuse (Votaw et al., in
press).
The misuse of tranquilizer vs. sedative medications differentiated these two
classes, given that model entropy increased substantially when these indicators were
added to the model. Among NSDUH respondents, the most commonly misused
tranquilizer products are benzodiazepines, while the most commonly misused sedatives
are zolpidem products (though both categories include benzodiazepine products) (Hughes
et al., 2016). Thus, polysubstance use might be particularly common among those with
benzodiazepine misuse, but not among those who only misuse other tranquilizers and
sedatives. Although numerous analyses of NSDUH data have combined tranquilizer and
sedative categories (Becker et al., 2007; Goodwin & Hasin, 2002; Votaw et al., 2019),
results of the present analysis indicate that those with tranquilizer vs. sedative misuse are
distinct groups, with considerably different patterns of polysubstance use. These findings
support a recent call by our research group to evaluate benzodiazepines separately from
other tranquilizers and sedatives in population-based surveys (Votaw et al., in press).
Pending this substantial change, researchers should consider tranquilizers and sedatives
separate prescription drug classes when analyzing NSDUH data.
As hypothesized, younger age was associated with greater odds of membership in
the tranquilizer misuse with high polysubstance use class. This is consistent with prior
latent class analyses of epidemiological surveys finding that younger age is associated
with high polysubstance use classes among those with alcohol use disorder (Moss,
Goldstein, Chen, & Yi, 2015) and stimulant misuse (Chen et al., 2014). Educating young

25

TRANQUILIZER/SEDATIVE MISUSE AND PATTERNS OF POLYSUBSTANCE
USE
adults about the harms of combining tranquilizers and sedatives with other substances
might reduce rates of overdoses in this group.
Contrary to our hypothesis, and to other latent class analyses of polysubstance use
among general population samples (Chen et al., 2014; Moss et al., 2015), gender was not
associated with expected class membership. Other studies have also found few
differences between women and men on tranquilizer and sedative misuse prevalence and
consequences. Although men are generally at higher risk for alcohol and most illicit
substance use, gender is not consistently associated with risk of tranquilizer and sedative
misuse (Votaw et al., in press). Women and men who misuse tranquilizers and sedatives
have similar rates of emergency department visits related to opioids and benzodiazepines
(C. M. Jones & McAninch, 2015), injection benzodiazepine use (Shane Darke, Topp, &
Ross, 2002; Ross, Darke, & Hall, 1997), treatment attrition (Schiff et al., 2007), and
unsafe sex (Davies, Dominy, Peters, & Richardson, 1996). Thus, findings from the
present analysis contribute to a growing body of literature indicating that women with
tranquilizer and sedative misuse have similar profiles of substance use severity as men.
Psychiatric distress was also unrelated to latent class membership in the present
analysis. Nevertheless, the sample as a whole reported elevated psychiatric distress,
which is consistent with findings that psychiatric distress increases risk of tranquilizer
and sedative misuse (Votaw et al., in press). It is important to note that we utilized a
general measure of psychiatric distress. Previous studies have found that anxiety
sensitivity is associated with benzodiazepine misuse frequency among those with opioid
use disorder (McHugh et al., 2017), and that specific psychiatric disorders (e.g., major
depressive disorder, social phobia, personality disorders) are associated with latent class
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membership in high polysubstance use classes among those with alcohol use disorder
(Moss et al., 2015). It is possible that specific measures of affective vulnerabilities and/or
psychiatric disorders might be associated with polysubstance use among those with
tranquilizer and sedative misuse. However, a latent class analysis examining patterns of
polysubstance use among those with stimulant misuse found that the same measure of
psychiatric distress used in the present analysis (K6 scores) was associated with
membership in high polysubstance use classes (Chen et al., 2014). These findings
indicate that psychiatric distress might not influence—or be influenced by—
polysubstance use among those with tranquilizer or sedative misuse.
A greater number of motives for tranquilizer or sedative misuse was associated
with membership in the tranquilizer misuse with high polysubstance use class. Those
who use multiple substances might display more substance-specific motives for
tranquilizer and sedative misuse, such as withdrawal relief and modifying the effects of
other substances, in addition to more common motives, such as negative affect relief and
enhancement. This is consistent with evidence that individuals with substance use
disorders typically display multiple motives for benzodiazepine misuse (Votaw et al., in
press). Accordingly, myriad factors might influence the development and maintenance of
a pattern of polysubstance use among those with tranquilizer and sedative misuse.
Cognitive-behavioral treatments for substance use disorders typically address craving,
negative affect, decision-making, and interpersonal functioning (Carroll & Kiluk, 2017).
Such multifaceted treatments might be particularly useful for reducing polysubstance use
among those with tranquilizer and sedative misuse.
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Those who reported nonmedical use of tranquilizer and sedatives (e.g., using
without a prescription), as opposed to medical misuse (e.g., using at higher doses or for
longer periods of time than prescribed), were also more likely to be classified in the
tranquilizer misuse with high polysubstance use class. There are a number of potential
explanations for this association. First, the most commonly misused drug in the
tranquilizer category is alprazolam (Hughes et al., 2016), which is also one of the most
commonly prescribed prescription medications in the U.S. (Lindsley, 2012). Therefore,
tranquilizers might be more commonly diverted, and therefore available for use without a
prescription, than medications in the sedative category. Those who display a pattern of
polysubstance use might also have greater access to nonmedical sources of tranquilizers
and sedatives, such as purchasing these medications from a drug dealer. Lastly, a third
factor might influence both polysubstance use and likelihood of receiving
tranquilizers/sedatives from nonmedical sources, such as impulsivity and perceptions of
risk. As we previously noted in a systematic review, developing screening measures for
benzodiazepine misuse should be a research priority (Votaw et al., in press). These
screening measures might incorporate distinctions between nonmedical use and medical
misuse in order to identify those who are at the greatest risk of polysubstance use and, by
extension, overdose.
Interestingly, results of the distal outcomes analysis only identified one significant
effect—those in the tranquilizer misuse with high polysubstance use class were
significantly more likely to be arrested in the past year, as compared to those in the
sedative misuse with low polysubstance use class. These findings might be explained by
a greater likelihood of drug-related arrests among those with polysubstance use, such as
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possession and trafficking. It is surprising that a high polysubstance use profile was not
associated with other consequences of interest, including STI, injection drug use, deviant
behaviors, and suicidal ideation. More broadly, these findings indicate that some
associations between tranquilizer/sedative misuse and functional consequences are not
attributable to polysubstance use. Yet, the examined functional consequences were highly
prevalent among the whole sample of adults with past-month tranquilizer and sedative
misuse (see Figure 2). These findings indicate that characteristics of those with
tranquilizer and sedative misuse, such as elevated psychiatric distress, or pharmacological
effects of tranquilizers and sedatives, such as disinhibition, might contribute to these
functional consequences. However, information on overdose and several other
consequences associated with misuse (e.g., treatment attrition, unsafe sex) was not
available in the NSDUH survey, and therefore we cannot conclude that polysubstance use
does not contribute to any consequences associated with tranquilizer and sedative misuse.
The present analysis is limited by several methodological features. First, data
from the present study are cross-sectional and only include non-institutionalized, civilian
citizens. Therefore, we cannot make temporal or causal conclusions about findings from
the present analysis, and excluding certain subgroups (e.g., incarcerated individuals,
those in substance use disorder treatment) might obscure population estimates of
substance use. Although a relatively small proportion of our sample was missing data on
predictor variables (1.8% of eligible respondents) or functional outcome variables (4.0%
of those included in the LCA), those with missing data were significantly different than
those without missing data on several LCA indicators. Unfortunately, MPlus cannot
accommodate missing data techniques, such as multiple imputation, with complex survey
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designs. The inability to include those with missing data on predictors or functional
outcomes might influence the reliability and generalizability of study findings. In
addition, information on several factors relevant to the research questions, including
specific measures of psychiatric disorders (e.g., affective vulnerabilities, psychiatric
diagnoses) and overdose, are not available in the NSDUH public use data file. Our
findings also reflect the concurrent misuse of tranquilizers and sedatives with other
substances, as opposed to simultaneous use (i.e., co-ingestion). Future studies are needed
to examine patterns of simultaneous substance use among those with tranquilizer and
sedative misuse.
In conclusion, a majority of individuals with tranquilizer or sedative misuse in a
general population sample displayed a pattern of polysubstance use. The high
polysubstance use class was also characterized by high probabilities of tranquilizer
misuse and low probabilities of sedative misuse, likely indicating that polysubstance use
is particularly common among those with benzodiazepine misuse. This finding is
concerning, given that benzodiazepines increases risk of overdose when combined with
other substances (J. D. Jones et al., 2012). It is important to note that the sedative with
low polysubstance use class also had moderate probabilities of binge alcohol
(approximately 36%), marijuana (17%), and prescription opioid misuse (18%), and
therefore those with expected membership in this class might also be at heightened risk of
overdose. Interventions to reduce polysubstance use and associated consequences among
those with tranquilizer and sedative misuse should target young adults and those who
report nonmedical use of these medications, and should address myriad motives for
misuse. Longitudinal studies are needed to examine temporal relationships between
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tranquilizer and sedative misuse onset, the development of a pattern of polysubstance use,
and functional consequences.
Study 2: Clinical Sample
Method
Data source and participants. Participants were recruited from the inpatient
detoxification unit of McLean Hospital (located in Belmont, Massachusetts) as part of a
larger survey study characterizing individuals receiving inpatient detoxification treatment
for substance use disorders. Inclusion criteria for this study required that participants
were least 18 years of age, were receiving treatment for a substance use disorder, were
not experiencing an acute medical/psychiatric disorder that would interfere with
participation, and were not involuntarily admitted to treatment. The study was described
to participants as research to understand how drugs and alcohol affect peoples’ lives. If
interested, participants first provided informed consent and then completed a battery of
self-report questionnaire on an iPad, which took approximately 30 minutes to complete.
Study staff could also read the survey to participants, if necessary (e.g., issues with
eyesight, unfamiliar with iPads) or if requested by the participant. In addition, primary
substance use disorder diagnoses were extracted from participants’ medical charts.
Data collection for the larger study has been ongoing since 2013; four iterations
(versions) of this study have been completed (N=1,351). Each version of the study
includes distinct research questions, and therefore different questionnaires are included.
For the present analysis, we combined all four versions and included respondents who
reported past-month misuse of benzodiazepines or other tranquilizers/sedatives (N=451,
33.4% of those enrolled in the larger study). Participants were primarily receiving
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treatment for opioid use disorder (n=263, 58.3% of the study sample) and alcohol use
disorder (n=139, 30.8%), though a minority were receiving treatment for other substance
use disorders (n=49, 10.9%).
Measures.
Sociodemographics. The following sociodemographic measures were included in
the present analysis: sex and age. We chose not to include racial/ethnic identity as a
predictor in this sample, given the low rate of respondents who did not identify as nonHispanic White (6.4%).
Substance use. The Brief Addiction Monitor was utilized to assess past-month
substance use (Cacciola et al., 2013). Participants reported their frequency of past-month
use for the following substances: alcohol, benzodiazepines (benzos, Valium, Xanax,
Ativan, Klonopin, clonazepam, etc.), other tranquilizers/sedatives (Ambien, barbs,
Phenobarbital, downers, etc.), cocaine/crack cocaine, other stimulants (amphetamine,
methamphetamine, Dexedrine, Ritalin, Adderall, speed, crystal meth, ice, etc.), heroin,
other opioids (Oxycontin, oxycodone, Vicodin, Percocet, Morphine, Dilaudid, Demerol,
codeine, Tylenol 3, Fentanyl, etc.), and inhalants (glue, adhesives, nail polish remover,
paint thinner, etc.). Participants were instructed to only report illicit use or misuse of
prescription substances and marijuana. Participants in Versions 1 and 2 reported
frequencies of use, based on categorical response options (0, 1–3, 4–8, 9–15, or 16–30
days), while those in Versions 3 and 4 reported the total number of days they used the
substance in the past-month, as a continuous response. All substance use responses were
recoded into binary variables, indicating whether the participant used each substance in
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the previous month (yes vs. no). Continuous frequencies of use in Versions 3 and 4 were
recoded into the categorical frequencies used in Versions 1 and 2.
Physical and mental health. The Anxiety Sensitivity Index-3 (ASI-3) was
included as a measure of anxiety sensitivity, or the fear of anxiety symptoms and
sensations. Participants rate their agreement (e.g., “very little” to “very much”) with a
total of 18 items. Examples of items include the following: “I worry that other people will
notice my anxiety.”, “I think it would be horrible for me to faint in public.”, and “It
scares me when I blush in front of people.” The potential range of responses ranged from
0 to 72, with higher scores representing greater anxiety sensitivity. Among participants in
the present study with complete data on the ASI-3 (n=413), the measure demonstrated
excellent internal consistency reliability (Cronbach’s α=.93).
The Overall Anxiety Symptom and Impairment Scale (OASIS) was included as a
measure of state anxiety that includes 5 questions about frequency, severity, and
interference (e.g., avoidance, role impairment, social impairment) of anxiety symptoms in
the previous week. Responses for each item range from 0 to 4, representing a potential
range of scores from 0 to 20; higher scores indicate more anxiety symptoms and greater
severity/interference of these symptoms (Campbell-Sills et al., 2009). Among participants
in the present study with complete data on the OASIS (n=435), the OASIS demonstrated
good internal consistency reliability (Cronbach’s α=.87).
The Brief Pain Inventory (BPI) was used to measure chronic pain and pain
interference with daily life. Participants were asked whether they had experienced any
pain on the day they completed the survey, excluding pain from withdrawal. If
participants responded affirmatively, they were asked to indicated the amount of time
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they had been experiencing that pain. If participants reported experiencing pain for at
least three months, they were categorized as having chronic pain. Those with chronic
pain then answered 7 questions to determine the extent to which pain interferes with daily
life, including interference with general activity, mood, walking activity, normal work,
relationships, sleep and enjoyment of life. Response options ranged from 0 to 10, and
total pain interference scores represented a mean of all 7 questions. Among those with
chronic pain and complete BPI data in our sample (n=90), the pain interference subscale
demonstrated excellent internal consistency reliability (Cronbach’s α=.90). For the
purpose of the present analysis, those without chronic pain were assigned a score of 0 on
the pain interference variable. Two BPI variables were included in the present analysis:
chronic pain and pain interference.
Proposed analyses. First, we utilized latent class analysis (LCA) to identify
patterns of polysubstance use in the month prior to hospitalization. Indicators for the
current analysis were past-month binge alcohol use and misuse of prescription
medications (e.g., prescription amphetamines, prescription opioids) and illicit drugs (e.g.,
marijuana, cocaine, heroin, etc.). For substances that were endorsed by <5% of the
sample, we either combined use of these substances with other substances of the same
class (e.g., prescription opioids and heroin) or excluded these substances as an indicator
in the LCA. We started with a 1-class solution and proceeded until the optimal model was
identified. Model fit was assessed using the Bayesian Information Criteria (BIC), where a
lower BIC indicates a better fitting model, and the sample size adjusted Bayesian
Information Criteria (aBIC), which adds a penalty for increasing parameters related to
sample size. The optimal number of classes was identified by the lowest BIC and aBIC
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(or the greatest rate of decrease in BIC) and theoretical interpretability. Notably, we did
not report the Lo-Mendell-Rubin adjusted likelihood ratio test (LRT) as an indicator of
model fit given that MPlus does not provide LRT estimates when multiple imputation is
utilized to account for missing data (see below for details on multiple imputation). We
also evaluated classification precision using model entropy.
All models were estimated with three different combinations of indictors to
identify the most theoretically interpretable model. First, indicators for the latent class
analysis were included as binary (yes/no) past-month use of binge alcohol and
illicit/prescription substances (LCA iteration 1). Second, for substances that were used by
a high proportion of the sample in the previous month (i.e., >50%), categorical frequency
indicators were utilized (LCA iteration 2). Lastly, a frequency indicator for past-month
benzodiazepine misuse and a binary indicator for other tranquilizer/sedative misuse in the
previous month were added to the model (LCA iteration 3).
Potential predictors of latent class membership were included as covariates in the
LCA. Results are interpreted as a multinomial logistic regression, with latent class
membership as a categorical outcome variable. Based on prior evidence of association
with tranquilizer/sedative misuse incidence and severity (Votaw et al., in press),
predictors for the clinical sample will include: age, gender, past-week anxiety symptoms
(OASIS score), anxiety sensitivity (ASI-3 score), presence of chronic pain, and pain
interference (BPI score). Effect sizes represent odds ratios, adjusting for all covariates in
the model (aOR).
SPSS version 25 was used to prepare data; all other analyses were conducted in
MPlus version 8 (L. Muthén & Muthén, 2017). Seventy-four participants (16.4% of the
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total sample) were missing data on at least one predictor variable. As compared to those
without missing data, participants with missing data on predictor variables were
significantly older (M age=34.39 years vs. 30.89 years; t(449)=-2.53, p=.012), were more
likely to report cocaine use in the previous month (63.5% vs. 50.5%; X2(1)=4.17,
p=.041), and were more likely to report 16+ days of use in the previous month for the
following substances: benzodiazepines (40.5% vs. 26.5%; X2(1)=5.92, p=.015), binge
alcohol (35.6% vs. 23.3%; X2(1)=4.87, p=.027), cocaine (27.0% vs. 8.0%; X2(1)=22.51,
p<.001), and prescription opioids (37.8% vs. 24.5%; X2(1)=5.59, p=.018). Therefore, data
were assumed to be missing at random (MAR), given that they were associated with
other measured variables in the proposed models. Missing data were imputed using
multiple imputation procedures in MPlus prior to calculating descriptive statistics and
conducting the proposed latent class analyses (Asparouhov & Muthén, 2010). Parameter
estimates were pooled across 50 imputed data sets. Imputation models included all
indicators and covariates/predictors, as well as other variables of interest reported in
descriptive statistics (e.g., employment, education, primary substance use disorder).
Results
Descriptive statistics. Sociodemographic, clinical, and substance use data are
presented in Table 6. The sample was 31.5 years of age (SD=10.9), on average. A
majority of the sample was male (69.3%), unemployed (58.6%), and received less than a
college education (77.5%). Participants reported an average ASI-3 score of 28.1
(SD=16.5), representing high levels of anxiety sensitivity (Allan et al., 2014). This is
consistent with evidence that high anxiety sensitivity increases risk of tranquilizer and
sedative misuse (Conrod et al., 2000; Hearon et al., 2011; McHugh et al., 2017). The
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sample reported a mean OASIS score of 12.8 (SD=4.3), which is comparable to scores
reported by a sample of individuals with anxiety disorder diagnoses (Campbell-Sills et
al., 2009). Given that the OASIS is a measure of anxiety symptoms in the past week, it is
possible that high scores were influenced by acute withdrawal symptoms experienced
during detoxification. A total of 31.1% of participants reported experiencing chronic
pain, and the average level of pain interference among the whole sample (including those
with and without chronic pain) was 1.5 (SD=2.6).
Participants primarily reported past-month benzodiazepine misuse only (73.7%),
followed by the misuse of both benzodiazepines and other tranquilizers/sedatives
(23.4%), and the misuse of other tranquilizers/sedatives only (2.9%). The incidence and
frequency of use for each substance category is presented in Table 7. Other than
benzodiazepines, binge alcohol use was the most frequently reported substance category,
followed by prescription opioids, heroin, and marijuana. Inhalant use was not included in
the present analyses due to the low rate of use in the sample (4.2% of the sample).
Latent class analyses. BIC, aBIC, and entropy for the 1- through 4-class
solutions for all three iterations of indicators are presented in Table 8. As previously
described, models were first estimated for the LCA with binary (yes/no) indicators for
past-month binge alcohol, marijuana, prescription opioid, cocaine, heroin, stimulant, and
other drug use. In LCA iteration 2, binary indicators were retained for past-month heroin,
stimulant, and other drug use, but frequency indicators (0, 1–3, 4–8, 9–15, or 16–30 days)
were utilized for substances used by >50% of the sample, including binge alcohol use,
marijuana, prescription opioids, and cocaine. Although heroin use was reported by >50%
of participants, the majority of participants either did not use heroin (39.4%) or misused
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heroin at the highest possible frequency (16+ days of use; 46.8%). Finally, in LCA
iteration 3, two indicators were added to the previous iteration: a frequency indicator for
past-month benzodiazepine misuse and a binary indicator for other tranquilizer and
sedative misuse.
For all three LCA iterations, BIC was lowest in the 2-class model, and highest in
the 1-class model. aBIC decreased from the 1- to 2-class models, from the 2- to 3-class
models, and from the 3- to 4-class models. However, in all three iterations, the rate of
aBIC decrease was greatest from the 1- to 2-class models. To prevent over-extraction of
latent classes and to increase parsimony, we selected the 2-class solution of LCA iteration
3 as the final model; this model was also chosen for theoretical interpretability. Entropy
for this model indicated that approximately 76.4% of participants were likely classified
correctly.
The probabilities of endorsing each substance category, by latent class, are
presented in Table 9. The first latent class (opioid use with high polysubstance use)
comprised approximately 73.1% of the sample. This latent class was characterized by
high probabilities of heroin, binge alcohol, marijuana, prescription opioid, and cocaine
use and moderate probabilities of stimulant and other drug use. The second latent class
(binge alcohol use with moderate polysubstance use) consisted of approximately 26.9%
of the sample and displayed high probabilities of binge alcohol use, moderate
probabilities of marijuana, prescription opioid, and other drug use, and low probabilities
of heroin, stimulant, and cocaine use. Interestingly, the binge alcohol use with moderate
polysubstance use class had a higher probability of misusing benzodiazepines 16 or more
days in the previous month (35.6% vs. 26.4%), while the opioid use with high
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polysubstance use class had a higher probability of misusing non-benzodiazepine
tranquilizers or sedatives in the previous month (29.7% vs. 16.9%).
Logistic regression. Results of the logistic regression predicting LCA class
membership are presented in Table 10. Older age (aOR=0.89, 95% CI=0.85, 0.94,
p<0.001) and higher anxiety sensitivity were (aOR=0.97, 95% CI=0.95, 0.99, p<0.030)
associated with lower odds of membership in the opioid use with high polysubstance use
class, as compared to the binge alcohol use with moderate polysubstance use class.
Gender, anxiety symptoms, chronic pain status, and pain interference were not associated
with class membership (ps>.05).
Discussion
The misuse of tranquilizer and sedative medications is associated with a range of
poor outcomes among those with substance use disorders, most notably increased risk of
overdose (Votaw et al., in press). Among those with substance use disorders, the use of
other substances is consistently associated with increased risk of tranquilizer and sedative
misuse (Votaw et al., in press). Yet, little is known about patterns of polysubstance use
among those who misuse these medications. We identified two latent classes of
polysubstance use among those in substance use disorder treatment who reported pastmonth tranquilizer/sedative misuse: opioid misuse with high polysubstance use and binge
alcohol use with moderate polysubstance use. Notably, the opioid use with high
polysubstance use class comprised over 70% of participants in our sample. It is
concerning that a majority of participants with tranquilizer and sedative misuse displayed
a high polysubstance use profile, given that tranquilizers and sedatives increase risk of
overdose when combined with other substances (Gudin et al., 2013). Findings from the
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present analysis also provide information on risk factors for a high polysubstance use
profile that might help inform targeted prevention and treatment efforts.
Patterns of polysubstance use identified in the present analysis partially supported
our hypothesis that we would identify three latent classes reflecting: (1) concurrent
alcohol use, (2) concurrent opioid use, and (3) high levels of polysubstance use. Instead,
two classes were identified and interpreted as opioid use with high polysubstance use and
binge alcohol use with moderate polysubstance use. It is therefore possible that identified
correlates of expected latent class membership might reflect factors associated with
opioid use disorder vs. alcohol use disorder. Several item response probabilities identified
in the present latent class analysis were somewhat surprising. In particular, the binge
alcohol use with moderate polysubstance use class had a higher probability of misusing
benzodiazepines 16 or more days in the previous month, as compared to the opioid use
with high polysubstance use class (35.6% vs. 26.4%). This class also had a moderate
probability of reporting past-month prescription opioid misuse, particularly at the highest
frequency (16+ days; 28.4%). Given moderate to high probabilities of binge alcohol,
benzodiazepine, and prescription opioid misuse, the binge alcohol use with moderate
polysubstance use class might have similar overdose risk as the opioid use with high
polysubstance use class.
As expected, younger age was associated with membership in the opioid use with
high polysubstance use class. Findings on the association between age and risk of
tranquilizer/sedative misuse have been inconsistent among those with substance use
disorders (Votaw et al., in press). However, younger age is also associated with
polysubstance use among individuals in substance use disorder treatment (Timko, Ilgen,
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Haverfield, Shelley, & Breland, 2017) and those with opioid use disorder in the general
population (Hassan & Le Foll, 2019). Psychoeducation on the risks of combining
tranquilizers and sedatives with other substances should be targeted to young adults with
substance use disorders.
Contrary to our hypothesis, gender was not associated with latent class
membership. One previous study among those with opioid use disorder in the general
population found that male gender was associated with greater polysubstance use (Hassan
& Le Foll, 2019), but another study among those in substance use disorder treatment
found that gender was not associated with polysubstance use patterns (Timko et al.,
2017). Males comprised the majority of the sample in the present analysis (70%) and in
the previous analysis of individuals in substance use disorder treatment (90%; Timko et
al., 2017). Limited representation of female participants might have contributed to null
findings. However, previous studies have not identified gender differences in risk of
tranquilizer/sedative misuse (Votaw et al., in press) or in several consequences associated
with misuse (e.g., hospitalizations, injection use, treatment attrition, HIV/HCV risk
behaviors) (Davies et al., 1996; C. M. Jones & McAninch, 2015; Ross et al., 1997; Schiff
et al., 2007). Although women might be more likely than men to misuse tranquilizers and
sedatives to cope with negative affect (Votaw et al., in press), there appear to be few
gender differences with respect to overall substance use severity. These findings
underscore the need for research on sex and gender differences in the development and
maintenance of benzodiazepine misuse.
Interestingly, anxiety sensitivity was associated with membership in the binge
alcohol use with moderate polysubstance use class, as opposed to the opioid use with
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high polysubstance use class. This unexpected finding might be explained by more
frequent benzodiazepine misuse among those in the binge alcohol use with moderate
polysubstance use class, given that anxiety sensitivity has previously been associated
with higher frequency of benzodiazepine misuse among those with opioid use disorder
(McHugh et al., 2017). Different motives for tranquilizer/sedative misuse between these
two classes might also contribute to this finding. For example, those in the opioid use
with high polysubstance use class could have more motives for tranquilizer and sedative
misuse (e.g., to cope, for withdrawal, to get high, to modify the effects of other
substances), while those in the binge alcohol use with moderate polysubstance use class
might misuse these medications primarily to cope with negative affective and somatic
states. Nevertheless, the magnitude of the association between anxiety sensitivity and
latent class membership was small and the sample as a whole displayed a high level of
anxiety sensitivity. Targeting anxiety sensitivity with psychosocial treatments (e.g.,
cognitive behavioral therapy) might help reduce tranquilizer/sedative misuse, regardless
of polysubstance use profile.
Neither chronic pain nor pain interference was associated with latent class
membership in the present analysis. However, two previous studies found that chronic
pain and pain severity were associated with tranquilizer/sedative misuse among those
with heroin use (Moses, Lundahl, & Greenwald, 2018) and injection drug use (Hassan &
Le Foll, 2019). Accordingly, pain appears to be associated with tranquilizer and sedative
misuse (either as an antecedent or consequence), but not necessarily with polysubstance
use among those with misuse. This finding might also be explained by similar
probabilities of prescription opioid misuse in both latent classes, given the strong link
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between pain and risk of prescription opioid misuse (Voon, Karamouzian, & Kerr, 2017).
Indeed, there is a robust and consistent association between the misuse of prescription
opioids and tranquilizer/sedatives (Votaw et al., in press), and therefore previous findings
indicating that pain is a risk factor for tranquilizer/sedative misuse might be confounded
by prescription opioid misuse. Longitudinal studies are needed to elucidate these
relationships. Specifically, it is unclear if individuals misuse tranquilizers and sedatives
to relieve pain, if hyperalgesia is a consequence of misuse, or if the association between
pain and tranquilizer/sedative misuse is attributable to prescription opioid misuse.
There are several limitations to the present analysis. First, neither causality nor
temporality can be inferred from the present results given that this was a cross-sectional
analysis. Second, individuals in the present analysis were receiving inpatient
detoxification treatment, and therefore findings might not generalize to non-treatmentseeking individuals. In particular, scores on the OASIS and pain items might have been
influenced by acute detoxification, even though participants were instructed to not report
pain due to withdrawal. These findings might also have limited generalizability to racial
and ethnically diverse populations, give than over 90% of the present sample identified as
Non-Hispanic White. In addition, information was not collected on several factors that
might help explain findings of the present analysis, such as motives for tranquilizer and
sedative misuse and overdose history. Lastly, patterns of polysubstance use identified in
the present analysis reflect the concurrent use of these substances, as opposed to coingestion. Given that co-ingestion contributes to drug overdose, future studies are needed
to identify substances that are most commonly co-ingested with tranquilizers and
sedatives.
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In conclusion, a majority of those with tranquilizer and sedative misuse in the
present analysis were classified in the opioid use with high polysubstance use class.
Younger age was associated with membership in the opioid use with high polysubstance
use class, indicating that psychoeducation on the risks of combining tranquilizers and
sedatives with other substances could be particularly useful for young adults.
Interventions targeting anxiety sensitivity might also have promise in reducing
tranquilizer and sedative misuse, particularly among those with binge alcohol use and
moderate polysubstance use. Addressing polysubstance use among those with
tranquilizer/sedative misuse is critical to reduce overdose deaths involving these
medications
Overall Conclusion
The overall aim of the present study was to examine patterns of polysubstance use
among those with tranquilizer and sedative misuse in two distinct samples: those in the
general population and those receiving substance use disorder treatment. A majority of
individuals with tranquilizer and sedative misuse, both in the general population and
among those in substance use disorder treatment, displayed high polysubstance use
profiles. This is consistent with numerous previous analyses indicating that the use of
multiple substances is a robust risk factor for tranquilizer and sedative misuse (Votaw et
al., in press). These findings are concerning given that tranquilizers and sedatives
increase risk of heart rate and respiratory depression when combined with other
substances (Gudin et al., 2013).
We also aimed to examine correlates of latent class membership in order to
identify potential risk factors for more severe polysubstance use. In the general
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population sample, those in the tranquilizer misuse with high polysubstance use class
were younger, displayed more motives for misuse, and were more likely to misuse
tranquilizers/sedatives without a prescription. In the clinical sample, the opioid use with
high polysubstance use class was also younger and had lower anxiety sensitivity.
However, as a whole, the general population sample reported elevated levels of
psychiatric distress and the clinical sample had anxiety sensitivity scores similar to those
reported by individuals with anxiety disorders. Taken together, young adults with
tranquilizer and sedative misuse and those who report misuse without a prescription
might benefit from targeted interventions to reduce polysubstance use, including
psychoeducation. Prevention and treatment efforts should address negative affect,
including anxiety sensitivity, as well as the range of motives for which tranquilizers and
sedatives are used, including coping with negative affective and somatic states, getting
high, and modifying other drug effects.
Lastly, we examined functional consequences associated with identified latent
classes. The primary reason for this aim was to determine if functional consequences
previously associated with tranquilizer/sedative misuse (e.g., STI, suicidal ideation,
criminality, injection drug use) might be partly attributable to polysubstance use.
However, those in the tranquilizer misuse with high polysubstance use class only differed
from those in the sedative misuse with low polysubstance use class on one
consequence—rates of past year arrest. Instead, both latent classes displayed high rates of
examined functional consequences, including STI, injection drug use, deviant behaviors,
and suicidal ideation. These findings indicate that characteristics of those with
tranquilizer or sedative misuse, such as elevated psychiatric distress, or pharmacological
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effects of tranquilizers and sedatives, such as disinhibition, might contribute to these
functional consequences.
These two analyses have several shared methodological limitations. Data from
both studies are cross-sectional and were based on retrospective, self-report measures.
Therefore, we are not able to draw temporal or causal inferences from study findings, and
findings might be influenced by recall bias. Both studies also utilized LCA, which is
probabilistic and has been criticized for reifying subgroups that do not exist
(Raudenbush, 2005). Accordingly, latent classes identified in the present analysis should
be interpreted as a heuristic for heterogeneity in polysubstance use among those with
tranquilizer and sedative misuse. Misclassification of participants in expected latent
classes could also cause spurious associations between predictors and expected latent
class membership, and between expected latent class membership and functional
outcomes (see Kamata, Kara, Patarapichayatham, & Lan, 2018). Lastly, we evaluated a
limited number of predictors of latent class membership in both studies, primarily due to
constraints on measures that were administered. It is possible that we overlooked relevant
variables, such as specific measures of psychiatric distress in the general population
sample and motives for tranquilizer/sedative misuse in the clinical sample.
Future research in this area is needed to determine if the use of other substances
precedes or follows the initiation of tranquilizer and sedative misuse, as well as motives
for these transitions. Such studies could help inform optimal timing and content for
prevention and treatment efforts to reduce polysubstance use among those with
tranquilizer and sedative misuse. As previously reviewed, there is also an urgent need for
screening measures to detect tranquilizer/sedative misuse (Votaw et al., in press). It
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would be valuable to determine the extent to which predictors of high polysubstance use
classes in the present analyses (e.g., younger age, nonmedical use) are useful for
detecting individuals at the highest risk of consequences related to tranquilizer and
sedative misuse. Lastly, longitudinal studies could help identify mechanisms underlying
the associations between tranquilizer/sedative misuse and poor functional outcomes, such
as behavioral disinhibition and increased psychiatric distress. Continued research in this
area has the potential to improve outcomes among those with tranquilizer and sedative
misuse, including reducing rates of overdose.
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Tables
Table 1. Sociodemographic, clinical, and substance use characteristics of the general
population sample (N=970)
Variable
Gender
Male
Female
Age
18-25
26-34
>35
Race/Ethnicity
Non-Hispanic White
Black/African American
Hispanic
Multiple Racial/Ethnic Identities
Other Racial/Ethnic Identity
Educational Attainment
Less than high school
High school graduate
Some college/associates degree
College graduate
Family Income
<$20,000
$20,000-$49,999
$50,000-$74,999
>$75,000
Psychiatric Characteristics
K6 Score
Substance Use Characteristics
Past-month tranquilizer misuse only
Past-month sedative misuse only
Past-month tranquilizer and sedative
misuse
Nonmedical use
Number of motives for misuse

57

N

Mean (SD) or
Percent

457
513

47.1%
52.9%

462
227
281

47.6%
23.4%
28.9%

692
92
114
52
20

71.3%
9.5%
11.8%
5.4%
2.1%

146
253
382
189

15.1%
26.1%
39.4%
19.5%

283
310
132
245

29.2%
32.0%
13.6%
25.3%

970

9.3 (6.1)

800
112

82.5%
11.5%

58
727
970

6.0%
74.9%
1.7 (1.1)
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Table 2. Incidence and frequency of past-month substance use among the general population sample (N=970)
No Use
Tranquilizers
Sedatives
Binge Alcohol Use
Marijuana
Prescription
Opioids
Cocaine
Hallucinogens
Heroin
Amphetamines

n
115
815
376
423

%
11.6%
82.5%
38.8%
43.6%

Any Use
n
%
873
88.4%
173
17.5%
594
61.2%
547
56.4%

626
825
851
910
746

64.5%
85.1%
87.7%
93.8%
76.9%

344
145
119
60
224

35.5%
14.9%
12.3%
6.2%
23.1%

1-3 Days of Use
n
%
534
54.0%
105
10.6%
251
25.9%
81
8.4%

4-8 Days of Use
n
%
193
19.5%
34
3.4%
186
19.2%
83
8.6%

9-15 Days of Use
n
%
87
8.8%
23
2.3%
98
10.1%
75
7.7%

16+ Days of Use
n
%
59
6.0%
11
1.1%
59
6.1%
308
31.8%

133
91
95
15
--

81
31
16
10
--

62
12
4
6
--

68
11
4
29
--

13.7%
9.4%
9.8%
1.5%
--

8.4%
3.2%
2.6%
1.0%
--

6.4%
1.2%
0.4%
0.6%
--

Note: Given the low rate of methamphetamine use in our sample (5.4%), methamphetamine use was combined with prescription
amphetamine use. Therefore, frequency of use for the overall amphetamine class is unavailable.

58

7.0%
1.2%
0.4%
3.0%
--
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Table 3. Indicators of model fit for the 1- through 4-class solutions for all three iterations of indicators in the general population
sample
Iteration 1: Indicators of Model Fit for Latent Class Analysis with Binary Indicators
2-Class Solution
3-Class Solution
1-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

4-Class Solution

22178.288

6070.813

6001.443

5993.644

22111.591

6000.941

5883.931

5828.492

1.000

0.656

0.721

0.699

Iteration 2: Indicators of Model Fit for Latent Class Analysis with Frequency Indicators for Binge Alcohol Use and
Prescription Opioid Use
1-Class Solution
2-Class Solution
3-Class Solution
4-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

24488.868

8365.167

8297.486

8330.245

24403.115

8257.183

8122.806

8088.869

1.000

0.660

0.723

0.705

Iteration 3: Indicators of Model Fit for Latent Class Analysis with Frequency Indicator for Tranquilizer Misuse and
Binary Indicator for Sedative Misuse
1-Class Solution
2-Class Solution
3-Class Solution
4-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

25861.012

9450.388

9151.231

9032.268

25778.435

9348.756

8986.079

8803.596

1.000

0.981

0.785

0.811
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Table 4. Incidence of past-month substance use by sedative misuse only, tranquilizer misuse only, and sedative and tranquilizer
misuse for the total general population sample (N=988)
Past-Month Sedative Misuse
Only (n=115)

Past-Month Tranquilizer
Misuse Only (n=815)

Past-Month Sedative and
Tranquilizer Misuse (n=58)

Substance Category
Binge Alcohol Use

n (%)
56 (48.7%)

n (%)
514 (63.1%)

n (%)
37 (63.8%)

X2
8.93*

Marijuana Use

31 (27.0%)

489 (60.0%)

36 (62.1%)

45.56**

Cocaine Use

8 (7.0%)

128 (15.7%)

12 (20.7%)

7.63*

Prescription Opioid
Misuse

28 (24.3%)

288 (35.3%)

35 (60.3%)

21.88**

Heroin Use

4 (3.5%)

51 (6.3%)

6 (10.3%)

3.19

Hallucinogen Use

8 (7.0%)

109 (13.4%)

7 (12.1%)

3.80

Amphetamine Use

14 (12.2%)

189 (23.2%)

25 (43.1%)

20.81**

Note: *p<0.05, **p<0.001
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Table 5. Logistic regression examining predictors of membership in the tranquilizer with high
polysubstance use class in the general population sample
Variable

b (SE)

aOR (95% CI)

p

Male
Female

Ref
-0.50 (0.29)

Ref
0.61 (0.35, 1.07)

0.085

18-25
26-34
35+

Ref
-0.92 (0.33)
-1.32 (0.32)

Ref
0.40 (0.21, 0.76)
0.27 (0.14, 0.50)

0.005
<0.001

Ref
0.057 (0.40)
0.63 (0.23)

Ref
1.06 (0.48, 2.34)
1.87 (1.19, 2.93)

0.887
0.006

Ref
0.82 (0.28)
0.03 (0.03)

Ref
2.27 (1.31, 3.91)
1.03 (0.98, 1.09)

0.003
0.240

Gender

Age

Race
Non-Hispanic White
Racial/Ethnic Minority
Number of motives for misuse
Nonmedical use
No
Yes
Psychiatric distress (K6 Score)
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Table 6. Sociodemographic, clinical, and substance use characteristics of the clinical sample
(N=451)
Variable
Sex
Male
Female
Age
College Graduate
No
Yes
Employed
No
Yes
Psychiatric Characteristics
ASI-3 score
OASIS score
Physical Health Characteristics
Presence of chronic pain (% yes)
Pain interference score

Mean (SD) or
Percent
69.3%
30.7%
31.5 (10.9)
77.5%
22.5%
58.6%
41.4%
28.1 (16.5)
12.8 (4.3)
31.1%
1.5 (2.6)

Substance Use Characteristics
Past-month benzodiazepine misuse
only

73.7%

Past-month other
tranquilizer/sedative misuse only

2.9%

Past-month benzodiazepine and other
tranquilizer/sedative misuse

23.4%
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Table 7. Incidence and frequency of past-month substance use among the clinical sample (N=451)

Benzodiazepines
Other Tranquilizers/
Sedatives
Binge Alcohol Use
Marijuana
Prescription Opioids
Cocaine
Heroin
Stimulants
Other Drugs

No Use

Any Use

1-3 Days of
Use

4-8 Days of
Use

9-15 Days of
Use

16+ Days of
Use

%
2.9%

%
97.1%

%
27.9%

%
22.6%

%
17.7%

%
28.8%

73.7%
36.4%
39.4%
37.6%
47.4%
39.4%
66.9%
69.5%

26.3%
63.6%
60.6%
62.4%
52.6%
60.6%
33.1%
30.5%

12.0%
14.5%
15.4%
13.8%
17.4%
4.2%
14.1%
7.6%

5.8%
11.4%
8.7%
13.6%
12.7%
5.6%
8.3%
10.2%

2.9%
12.4%
9.6%
8.2%
11.3%
4.0%
5.4%
6.5%

5.5%
25.3%
26.9%
26.8%
11.2%
46.8%
5.4%
6.2%
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Table 8. Indicators of model fit for the 1- through 4-class solutions for all three iterations of indicators in the clinical sample
Iteration 1: Indicators of Model Fit for Latent Class Analysis with Binary Indicators
2-Class Solution
3-Class Solution
1-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

4-Class Solution

17390.800

4074.617

4084.034

4119.751

17330.501

4007.971

3972.957

3964.244

1.000

0.775

0.680

0.675

Iteration 2: Indicators of Model Fit for Latent Class Analysis with Frequency Indicators for Binge Alcohol,
Prescription Opioid, Heroin, and Cocaine Use
2-Class Solution
3-Class Solution
4-Class Solution
1-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

20305.087

7016.821

7064.091

7140.872

20206.704

6874.008

6838.763

6833.03

1.000

0.767

0.754

0.781

Iteration 3: Indicators of Model Fit for Latent Class Analysis with Frequency Indicator for Benzodiazepine Misuse and
Binary Indicator for Other Tranquilizer/Sedative Misuse
2-Class Solution
3-Class Solution
4-Class Solution
1-Class Solution
Bayesian Information
Criteria (BIC)
Adjusted BIC
Entropy

22171.924

8905.147

8947.178

9044.745

22057.673

8730.597

8674.246

8673.43

1.000

0.764

0.736

0.756
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Table 9. Probabilities of endorsing each substance category by latent class in the clinical sample

Benzodiazepines
No Use
1-3 Days
4-8 Days
9-15 Days
16+ Days
Other Tranquilizers &
Sedatives (% Yes)
Binge Alcohol
No Use
1-3 Days
4-8 Days
9-15 Days
16+ Days
Marijuana
No Use
1-3 Days
4-8 Days
9-15 Days
16+ Days
Cocaine
No Use
1-3 Days
4-8 Days
9-15 Days
16+ Days
Prescription Opioids
No Use
1-3 Days
4-8 Days
9-15 Days
16+ Days
Stimulants (% Yes)
Heroin (% Yes)
Other Drugs (% Yes)

Opioid Use with High
Polysubstance Use

Binge Alcohol Use with
Moderate Polysubstance
Use

3.3%
26.4%
25.4%
18.5%
26.4%

1.7%
32.1%
15.2%
15.4%
35.6%

29.7%

16.9%

41.2%
17.0%
13.6%
11.7%
16.5%

23.5%
7.7%
3.2%
14.5%
49.1%

29.9%
16.6%
10.4%
11.4%
31.7%

65.3%
4.2%
4.2%
4.4%
14.0%

34.0%
21.4%
16.8%
14.5%
13.3%

83.9%
6.4%
1.6%
2.7%
5.4%

38.6%
15.7%
17.2%
10.3%
26.2%
40.0%
80.2%
32.6%

56.6%
8.6%
3.8%
2.6%
28.4%
14.3%
7.3%
24.7%
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Table 10. Logistic regression examining predictors of membership in the opioid misuse with
high polysubstance use class
Variable

b (SE)

aOR (95% CI)

p

Ref
0.43 (0.43)

Ref
1.53 (0.66, 3.54)

0.317

Age

-0.12 (0.03)

0.89 (0.85, 0.94)

<0.001

Anxiety Sensitivity (ASI-3 Score)

-0.03 (0.01)

0.97 (0.95, 0.99)

0.030

Anxiety Symptoms (OASIS Score)

0.05 (0.05)

1.05 (0.95, 1.16)

0.357

Ref
1.01 (0.91)

Ref
2.75 (0.47, 16.28)

0.264

-0.06 (0.15)

0.95 (0.70, 1.28)

0.721

Gender
Female
Male

Presence of Chronic Pain
No
Yes
Pain Interference (BPI score)
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Figures
Figure 1. Probabilities of endorsing each substance by latent class in the general population
sample
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Figure 2. Differences in functional outcomes by latent class in the general population sample

Note: *p<0.05
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